Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 4/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL29364719 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1FAHD1 | |
| Citric Acid SCHEMBL47867 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1FAHD1 | |
| Citric Acid SCHEMBL7004500 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1FAHD1 | |
| Citric Acid SCHEMBL430711 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL906010 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1FAHD1 | |
| Citric Acid SCHEMBL7921325 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL4727295 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL2974121 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1FAHD1 | |
| Citric Acid SCHEMBL41916 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL1716944 | 0.95 | CA4 (0.76) | CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295628-A1 | HIGHLY STABLE HEAVY METAL-REMOVING COMPOSITION, USE AND DOSAGE FORM THEREOF, AND PREPARATION METHOD THEREFOR | GUANGDONG JIANERSHENG PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2025-09-25 | — | — | US | claimed |
| WO-2025124483-A1 | ORAL DRUG DOSAGE FORM FOR TARGETED DRUG DELIVERY BASED ON TRACKING MARKER AND METHODS OF DESIGN AND USE THEREOF | Triastek, Inc. (CN) | 2025-06-19 | — | — | WO | claimed |
| US-12310941-B2 | Agent for protection of blood brain spinal cord barrier | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2025-05-27 | — | — | US | claimed |
| CN-119925329-A | Preparation method of bismuth potassium citrate oral solid preparation | 湖北丽益医药科技有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-119929874-A | Tin sulfide/bismuth sulfide composite material and preparation method and application thereof | 中国科学院山西煤炭化学研究所 | 2025-05-06 | — | — | CN | claimed |
| CN-115851463-B | Bradyyeast strain and application thereof | 天津芦台春酿造有限公司 | 2025-04-22 | — | — | CN | claimed |
| EP-4527382-A1 | HIGH-STABILITY HEAVY METAL REMOVING COMPOSITION, USE AND DOSAGE FORM THEREOF, AND METHOD FOR PREPARING SAME | Guangdong Jianersheng Pharmaceutical Technology Co., Ltd. (CN) | 2025-03-26 | — | — | EP | claimed |
| CN-119679057-A | Experimental canine osteoporosis model feed and preparation method and application thereof | 协同生物工程(扬州)有限公司 | 2025-03-25 | — | — | CN | claimed |
| CN-119606902-A | Dry granulating process of bismuth potassium citrate tablets | 河北科技大学 | 2025-03-14 | — | — | CN | claimed |
| CN-119534700-A | Method for measuring binding rate of bismuth and plasma protein in bismuth potassium citrate | 广东华南药业集团有限公司 | 2025-02-28 | — | — | CN | claimed |
| CN-101002769-A | Compound preparation of omeprazol | HUANAN PHARMACY CO LTD GUANGDO (CN) | 2007-07-25 | — | — | CN | claimed |
| CN-101002939-A | Medicine composition for treating diseases relating to gastric acid | HUANAN PHARMACEUTICAL CO LTD G (CN) | 2007-07-25 | — | — | CN | claimed |
| US-20070099799-A1 | Herbicide composition | SINON CORPORATION (TW) | 2007-05-03 | — | — | US | claimed |
| CN-1785180-A | Method for quality control of compound bismuth potassium citrate metronidazole | SHENQI GROUP CO LTD GUIZHOU (CN) | 2006-06-14 | — | — | CN | claimed |
| CN-1771940-A | Ulcer treating Western medicine prepn and its prepn process | GUIZHOU SHENQI GROUP HOLDING C (CN) | 2006-05-17 | — | — | CN | claimed |
| CN-1470253-A | Weishu capsule and its preparation method | 李 毅 | 2004-01-28 | — | — | CN | claimed |
| CN-1055865-C | X-ray colon special double-contrast contrast medium | WU QIQUAN (CN) | 2000-08-30 | — | — | CN | claimed |
| CN-1149494-A | X-ray colon special double-contrast contrast medium | WU QIQUAN (CN) | 1997-05-14 | — | — | CN | claimed |
| CN-1147380-A | Medicine compound for gastric and duodenal ulcer | ZHANG XIAOAN (CN) | 1997-04-16 | — | — | CN | claimed |
| CN-1080168-A | The preparation method of the Entogastric lingering slow releasing preparation of treatment digestive ulcer medicament | CONG FANZI (CN) | 1994-01-05 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099799-A1 | Herbicide composition | DDT, MTDH, GGH | CA4 52/4885ALDH1A1 1138/4885CASP1 4154/4885 |
| US-20250295628-A1 | HIGHLY STABLE HEAVY METAL-REMOVING COMPOSITION, USE AND DOSAGE FORM THEREOF, AND PREPARATION METHOD THEREFOR | SLC39A11, SLC39A7, SLC39A14 | CA4 197/4885ALDH1A1 522/4885CASP1 4209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.